The company
Acrivon Therapeutics, Inc.
ACRV · Nasdaq
ACRV stood above a rising 150-day average in 16 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 8.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 1
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $229K
- Insider sales, 12 months
- $80K
- Officials’ trades on record
- 0
- Institutions holding
- 42 (+2)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 16 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Mary MillerChief Legal Officer | sold | 294at $1.99 | 5 Oct 2026filed 7 Oct 2026 |
| Peter Blume-JensenPresident and CEO | sold | 14,036at $2.21 | 25 Aug 2026filed 27 Aug 2026 |
| Peter Blume-JensenPresident and CEO | sold | 1,229at $2.01 | 18 Aug 2026filed 20 Aug 2026 |
| Peter Blume-JensenPresident and CEO | sold | 484at $2.01 | 18 Aug 2026filed 20 Aug 2026 |
| Eric DevroeChief Operating Officer | sold | 604at $2.01 | 18 Aug 2026filed 20 Aug 2026 |
| Erick GamelinChief Development Officer | sold | 400at $2.01 | 18 Aug 2026filed 20 Aug 2026 |
| Mary MillerChief Legal Officer | sold | 185at $2.01 | 18 Aug 2026filed 20 Aug 2026 |
| Katharine PetersonChief Accounting Officer | sold | 101at $2.01 | 18 Aug 2026filed 20 Aug 2026 |
| Adam D. LevyChief Financial Officer | sold | 1,142at $1.57 | 4 Aug 2026filed 6 Aug 2026 |
| Mary MillerChief Legal Officer | sold | 573at $1.76 | 21 Jul 2026filed 23 Jul 2026 |
| Adam D. LevyChief Financial Officer | bought | 8,832at $1.70 | 14 Jan 2026filed 16 Jan 2026 |
| Peter Blume-JensenPresident and CEO | bought | 49,000at $1.68 | 14 Jan 2026filed 16 Jan 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.added · filed 14 Aug 2026 | 12,229,396$21.8M | +3,888,888+46.6% |
| Sands Capital Alternatives, LLCadded · filed 13 Aug 2026 | 2,289,271$4.1M | +166,666+7.9% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 952,008$1.7M | +229,973+31.9% |
| WELLINGTON MANAGEMENT GROUP LLPunchanged · filed 14 Aug 2026 | 888,130$1.6M | 00.0% |
| RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026 | 758,863$1.4M | +423+0.1% |
| TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026 | 641,498$1.1M | +252,103+64.7% |
| MARSHALL WACE, LLPreduced · filed 13 Aug 2026 | 531,856$947K | -28,580−5.1% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLCadded · filed 14 Aug 2026 | 378,900$674K | +220,000+138.5% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 265,241$472K | +28,850+12.2% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 239,112$426K | +30,173+14.4% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.